Merck KGaA’s lupus drug fails in Phase 2; Zymeworks pauses work on ADC
Plus, news about Tris Pharma and ARS Pharmaceuticals: Merck KGaA’s lupus drug flunks mid-stage trial: The drugmaker’s TLR7/8 inhibitor, called enpatoran, missed the primary response endpoint in a cohort of patients with systemic lupus erythematosus ...
Plus, news about Tris Pharma and ARS Pharmaceuticals:
Merck KGaA’s lupus drug flunks mid-stage trial: The drugmaker’s TLR7/8 inhibitor, called enpatoran, missed the primary response endpoint in a cohort of patients with systemic lupus erythematosus ...
